HAYWARD, Calif., May 20, 2022 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced that Chief Executive Officer,
Vince Angotti will present in-person
and be available for one-on-one meetings throughout the H.C.
Wainwright Global Investment Conference, to be held in person and
virtually May 23-26, 2022 in
Miami, FL.
H.C. Wainwright Global Investment Conference
Format:
Live presentation and 1x1 Meetings
Date: Tuesday, May 24th,
2022
Time: 3:30 PM EDT]
Webcast Link:
https://journey.ct.events/view/c7c39615-b777-44ea-aa7a-3c782e6247ac
The recorded presentation will also be available for 90 days on
AcelRx's website within the Investors/News/Events section.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's proprietary,
non-invasive sublingual formulation technology delivers sufentanil
with consistent pharmacokinetic profiles. The Company has one
approved product in the U.S., DSUVIA® (sufentanil sublingual
tablet, 30 mcg), known as DZUVEO® in Europe, indicated for the management of acute
pain severe enough to require an opioid analgesic for adult
patients in certified medically supervised healthcare settings, and
several product candidates. The product candidates include:
Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg),
an investigational product in the U.S. being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings; two pre-filled, ready-to-use syringes of ephedrine and
phenylephrine licensed for the U.S. from Aguettant; Niyad™, a
regional anticoagulant for the extracorporeal circuit; and LTX-608,
for the potential treatment of COVID-19, disseminated intravascular
coagulation, acute respiratory distress syndrome and acute
pancreatitis. DZUVEO and Zalviso are both approved products in
Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-participate-in-the-hc-wainwright-global-investment-conference-301552203.html
SOURCE AcelRx Pharmaceuticals, Inc.